Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
To determine whether the presenilin 1 (PS1), presenilin 2 (PS2) and amyloid beta-protein precursor (APP) mutations linked to familial Alzheimer's disease (FAD) increase the extracellular concentration of amyloid beta-protein (A beta) ending at A beta 42(43) in vivo, we performed a blinded comparison of plasma A beta levels in carriers of these mutations and controls. A beta 1-42(43) was elevated in plasma from subjects with FAD-linked PS1 (P < 0.0001), PS2N1411 (P = 0.009), APPK670N,M671L (P < 0.0001), and APPV7171 (one subject) mutations. A beta ending at A beta 42(43) was also significantly elevated in fibroblast media from subjects with PS1 (P < 0.0001) or PS2 (P = 0.03) mutations. These findings indicate that the FAD-linked mutations may all cause Alzhelmer's disease by increasing the extracellular concentration of A beta 42(43), thereby fostering cerebral deposition of this highly amyloidogenic peptide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ is produced by sequential β- and γ-secretase proteolytic cleavage of the amyloid precursor protein (APP) [11–17].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [11]
In the citing paper
“Similar to PSEN1 , PSEN2 mutations may also cause increased production of long A 𝛃 peptide species (481, 523), although this needs more investigation.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [523]
In the citing paper
“It is well established that this mutation causes concomitant increases in secreted A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In a previous study of human plasma (Scheuner et al., 1996), we showed that the Swedish APP K670N,M671L mutation increases both A42 and A40 and that other FAD-linked APP, PS1, and PS2 mutations selectively increase A42.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In that report, we suggested that cerebral A deposition in FAD occurs because of an increase in CNS A that develops as part of a generalized genetic effect that also increases plasma A.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationJarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citation
Cited by
Items 901–1,000 of 2,576
Shirotani, K., Tomioka, M., Kremmer, E., Haass, C., & Steiner, H. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.04.011 · Cited by 68
“…of rare genetic forms of the disease with mutations in the presenilin 1 (PS1) and presenilin 2 (PS2) and the APP gene has underlined the disease-causing role of Aβ42 since almost all of these familial AD (FAD) mutations cause an increased generation of this Aβ variant (Scheuner et al., 1996).”
BackgroundAmyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure
Vorobyeva, A. G., & Saunders, A. J. (2018) · Cilia · doi:10.1186/s13630-018-0059-y · Cited by 67
Co-aggregation with Apolipoprotein E modulates the function of Amyloid-β in Alzheimer’s disease
Xia, Z., Prescott, E. E., Urbanek, A., Wareing, H. E., King, M. C., Olerinyova, A., Dakin, H., Leah, T., Barnes, K. A., Matuszyk, M. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49028-z · Cited by 67
Kynurenines, neurodegeneration and Alzheimer’s disease
Kincses, Z. T., Toldi, J., & Vécsei, L. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01123.x · Cited by 68
Pathogenesis of Alzheimer’s Disease
Castellani, R. J., & Perry, G. L. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_162 · Cited by 67
Progress toward valid transgenic mouse models for Alzheimer’s disease
Guénette, S. Y., & Tanzi, R. E. (1999) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00042-1 · Cited by 74
Self-citationRoberson, E. D., & Kao, A. W. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511581410.010 · Cited by 67
A presenilin-1 mutation causes Alzheimer disease without affecting Notch signaling
Zhang, S., Cai, F., Wu, Y., Bozorgmehr, T., Wang, Z., Zhang, S., Huang, D., Guo, J., Shen, L., Rankin, C., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0101-x · Cited by 66
Roles of Extracellular Chaperones in Amyloidosis
Wyatt, A. R., Yerbury, J. J., Dabbs, R. A., & Wilson, M. R. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.01.004 · Cited by 72
Identification of the role of presenilins beyond Alzheimer?s disease
Thinakaran, G., & Parent, A. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2003.12.026 · Cited by 78
Mechanisms of Cerebrovascular Amyloid Deposition: Lessons from Mouse Models
BURGERMEISTER, P., CALHOUN, M. E., WINKLER, D. T., & JUCKER, M. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06381.x · Cited by 66
Winkler, E., Hobson, S., Fukumori, A., Dümpelfeld, B., Luebbers, T., Baumann, K., Haass, C., Hopf, C., & Steiner, H. (2009) · Biochemistry · doi:10.1021/bi801204g · Cited by 68
Suhara, T., Magrané, J., Rosen, K., Christensen, R., Kim, H.-S., Zheng, B., McPhie, D. L., Walsh, K., & Querfurth, H. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00135-5 · Cited by 70
Ertekin-Taner, N., Ronald, J., Feuk, L., Prince, J., Tucker, M., Younkin, L., Hella, M., Jain, S., Hackett, A., Scanlin, L., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi041 · Cited by 69
Self-citationHo, L., Fukuchi, K.-I., & Younkin, S. G. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.48.30929 · Cited by 66
Self-citationMohajeri, M. H., Wollmer, M. A., & Nitsch, R. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202899200 · Cited by 67
Frautschy, S. A., Horn, D. L., Sigel, J. J., Harris-White, M. E., Mendoza, J. J., Yang, F., Saido, T. C., & Cole, G. M. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-20-08311.1998 · Cited by 65
“Familial AD caused by genetic mutations is associated either with increased A! production of the more amyloidogenic peptide, A!1–42 (Scheuner et al., 1996; Selkoe, 1997), or, as with apolipoprotein E4 (ApoE4), with increased accumulation of A!40 (Ishii et al.”
BackgroundMaarouf, C. L., Daugs, I. D., Spina, S., Vidal, R., Kokjohn, T. A., Patton, R. L., Kalback, W. M., Luehrs, D. C., Walker, D. G., Castaño, E. M., et al. (2008) · Molecular Neurodegeneration · doi:10.1186/1750-1326-3-20 · Cited by 64
“It is widely accepted that a major pathological effect of PSEN mutations is a proportionately larger production of toxic Aβ42 [15-22].”
BackgroundSaura, C. A., Tomita, T., Soriano, S., Takahashi, M., Leem, J.-Y., Honda, T., Koo, E. H., Iwatsubo, T., & Thinakaran, G. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909624199 · Cited by 70
The role of presenilins in Alzheimer’s disease
Thinakaran, G. (1999) · Journal of Clinical Investigation · doi:10.1172/jci8728 · Cited by 66
Therapeutic induction of autophagy to modulate neurodegenerative disease progression
Hochfeld, W. E., Lee, S., & Rubinsztein, D. C. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.189 · Cited by 64
Khan, T. K., & Alkon, D. L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605411103 · Cited by 64
The PSEN1, p.E318G Variant Increases the Risk of Alzheimer's Disease in APOE-ε4 Carriers
Benitez, B. A., Karch, C. M., Cai, Y., Jin, S. C., Cooper, B., Carrell, D., Bertelsen, S., Chibnik, L., Schneider, J. A., Bennett, D. A., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003685 · Cited by 63
“Likewise, pathogenic mutations in the most important causal genes for familial AD, amyloid-beta precursor protein (APP), and presenilin 1 and 2 (PSEN1, PSEN2) alter CSF Ab42 levels [13,15,16].”
BackgroundUngureanu, A.-A., Benilova, I., Krylychkina, O., Braeken, D., Strooper, B. D., Haesendonck, C. V., Dotti, C. G., & Bartic, C. (2016) · Scientific Reports · doi:10.1038/srep25841 · Cited by 67
Plasma Aβ42 and Total Tau Predict Cognitive Decline in Amnestic Mild Cognitive Impairment
Chen, T., Lee, Y.-J., Lin, S.-Y., Chen, J.-P., Hu, C., Wang, P., & Cheng, I. H.-J. (2019) · Scientific Reports · doi:10.1038/s41598-019-50315-9 · Cited by 86
Funato, H., Enya, M., Yoshimura, M., Morishima‐Kawashima, M., & Ihara, Y. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65094-8 · Cited by 74
“Thus, the Ab concentrations in the extracellular space of CA1 showing NFT formation are orders of magnitude lower than those employed for in vitro neurotoxicity experiments; neurotoxicity of Ab is not observed up to 2.5 mmol/L in culture medium for dissociated cultured neurons8 and 25 mmol/L for organotypic hippocampa…”
ResultInfluentialEstrogen blocks neurotoxic effects of β-amyloid (1–42) and induces neurite extension on B103 cells
Mook‐Jung, I., Joo, I.-S., Sohn, S., Kwon, H. J., Huh, K., & Jung, M. W. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00632-0 · Cited by 64
Cantero, J. L., Iglesias, J. E., Van Leemput, K., & Atienza, M. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glw022 · Cited by 63
A novel mechanism for the regulation of amyloid precursor protein metabolism
Chen, Q., Kimura, H., & Schubert, D. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200110151 · Cited by 63
“, 1995), and an increased deposition of A in plaques has been associated with these mutations (Sherrington et al., 1995; Scheuner et al., 1996).”
BackgroundBohm, C., Chen, F., Sevalle, J., Qamar, S., Dodd, R., Li, Y., Schmitt-Ulms, G., Fraser, P. E., & St George-Hyslop, P. H. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.02.016 · Cited by 63
“Thus missense, splice site or duplication mutants in the presenilin 1 (PS1), presenilin 2 (PS2) or the amyloid precursor protein (APP) genes, which alter the levels or shift the balance of Aβ produced, are associatedwith rare, highly penetrant autosomal dominant forms of Familial Alzheimer's Disease (FAD).”
BackgroundKabir, M. T., Uddin, M. S., Jeandet, P., Emran, T. B., Mitra, S., Albadrani, G. M., Sayed, A. A., Abdel‐Daim, M. M., & Simal‐Gándara, J. (2021) · Marine Drugs · doi:10.3390/md19050251 · Cited by 71
“It has been revealed that there is a link between FAD mutations and increased ratio of Aβ42/40 [16,17], which indicates that increased Aβ42 levels (as compared to Aβ40) play a crucial role in AD pathogenesis, possibly via providing the core for Aβ assembly into amyloidogenic plaques, fibrils, and oligomers [18,19].”
BackgroundThe Novel Presenilin-1-associated Protein Is a Proapoptotic Mitochondrial Protein
Xu, X., Shi, Y.-C., Gao, W., Mao, G., Zhao, G., Agrawal, S., Chisolm, G. M., Sui, D., & Cui, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m209613200 · Cited by 67
Genetically modified pigs to model human diseases
Flisikowska, T., Kind, A., & Schnieke, A. (2013) · Journal of Applied Genetics · doi:10.1007/s13353-013-0182-9 · Cited by 70
Elevation in Plasma Abeta42 in Geriatric Depression: A Pilot Study
Pomara, N., Doraiswamy, P. M., Willoughby, L. M., Roth, A. E., Mulsant, B. H., Sidtis, J. J., Mehta, P. D., Reynolds, C. F., & Pollock, B. G. (2006) · Neurochemical Research · doi:10.1007/s11064-005-9029-z · Cited by 66
“Elevated plasma Ab42 levels have been reported in asymptomatic individuals with various APP, PS1, and PS2 mutations [39], which are deterministic for subsequent development of familial AD, as well as, in non-demented individuals with Down’s syndrome [40], a group who will inevitably develop AD with increasing age.”
BackgroundToward Structural Elucidation of the γ-Secretase Complex
Li, H., Wolfe, M. S., & Selkoe, D. J. (2009) · Structure · doi:10.1016/j.str.2009.01.007 · Cited by 63
Self-citationThe structure and function of Alzheimer’s gamma secretase enzyme complex
Krishnaswamy, S., Verdile, G., Groth, D. M., Kanyenda, L. J., & Martins, R. N. (2009) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408360903335821 · Cited by 73
Matheou, C. J., Younan, N. D., & Viles, J. H. (2015) · Biochemical Journal · doi:10.1042/bj20141168 · Cited by 64
Amyloid Beta Peptide-Induced Cerebral Neuronal Loss Is Mediated By Caspase-3 In Vivo
Takuma, H., Tomiyama, T., Kuida, K., & Mori, H. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.3.255 · Cited by 65
Verbeek, M. M., Eikelenboom, P., & de Waal, R. M. W. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199707000-00001 · Cited by 64
Membrane Topology of Alzheimer's Disease-related Presenilin 1
Nakai, T., Yamasaki, A., Sakaguchi, M., Kosaka, K., Mihara, K., Amaya, Y., & Miura, S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.23647 · Cited by 68
Early Onset Alzheimer’s Disease and Oxidative Stress
Meraz-Ríos, M. A., Franco-Bocanegra, D., Toral Rios, D., & Campos-Peña, V. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/375968 · Cited by 63
“Mutations in APP linked to EOAD include the Dutch (E693Q) [80], London (V717I) [74], Indiana (V717F) [77], Swedish (K670N/M671L) [81], Florida (I716V) [82], Iowa (D694N) [83], and Arctic (E693G) [84]mutations.”
BackgroundLongitudinal plasma amyloid beta as a biomarker of Alzheimer’s disease
Rissman, R. A., Trojanowski, J. Q., Shaw, L. M., & Aisen, P. S. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0772-4 · Cited by 62
“In subjects with familial AD or Down syndrome (DS), plasma Ab rises sharply before dementia onset, perhaps reflecting increased Ab production (Scheuner et al. 1996; Tokuda et al. 1997; Younkin 1998; Ertekin-Taner et al. 2000, 2008; Coppus et al. 2011).”
BackgroundThe pharmacology of amyloid precursor protein processing
Racchi, M., & Govoni, S. (2003) · Experimental Gerontology · doi:10.1016/s0531-5565(02)00158-4 · Cited by 72
“…to the longest APP isoform of 770 amino acids), or the mutations in PS, alter normal processing of the precursor and results in the formation of longer forms of the peptide (Kosaka et al., 1997; Scheuner et al., 1996; Suzuki et al., 1994) which are more susceptible to aggregation and deposition.”
Craft, D., Wein, L. M., & Selkoe, D. J. (2002) · Bulletin of Mathematical Biology · doi:10.1006/bulm.2002.0304 · Cited by 74
Wu, G., Hubbard, E. J. A., Kitajewski, J. K., & Greenwald, I. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15787 · Cited by 63
Genetic Testing for Alzheimer Disease: Practical and Ethical Issues
Roses, A. D. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550220036011 · Cited by 67
Armijo, E., González, C., Shahnawaz, M., Flores, A., Davis, B. R., & Soto, C. A. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.12.060 · Cited by 63
Munter, L.-M., Botev, A., Richter, L., Hildebrand, P. W., Althoff, V., Weise, C., Kaden, D., & Multhaup, G. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.088005 · Cited by 57
Is γ-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?
Checler, F., Afram, E., Pardossi-Piquard, R., & Lauritzen, I. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100489 · Cited by 59
Nicotinic receptors and Alzheimer's disease
Bourin, M., Ripoll, N., & Dailly, E. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125001631 · Cited by 61
Carrasquillo, M. M., Belbin, O., Zou, F., Allen, M., Ertekin‐Taner, N., Ansari, M., Wilcox, S. L., Kashino, M. R., Ma, L., Younkin, L. H., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008764 · Cited by 66
“[50,51].”
Self-citationGlycogen Synthase Kinase-3 in Neurodegeneration and Neuroprotection:Lessons from Lithium
Yadranji Aghdam, S., & Barger, S. (2007) · Current Alzheimer Research · doi:10.2174/156720507779939832 · Cited by 61
The Neurobiology and Pharmacotherapy of Alzheimer's Disease
Félician, O., & Sandson, T. A. (1999) · Journal of Neuropsychiatry · doi:10.1176/jnp.11.1.19 · Cited by 70
Hermans, M. M. P., Kroos, M. A., Smeitink, J. A. M., van der Ploeg, A. T., Kleijer, W. J., & Reuser, A. J. J. (1998) · Human Mutation · doi:10.1002/(sici)1098-1004(1998)11:3<209::aid-humu5>3.0.co;2-c · Cited by 27
Origin of the PSEN1 E280A mutation causing early‐onset Alzheimer's disease
Lalli, M. A., Cox, H. C., Arcila, M. L., Cadavid, L., Moreno, S., Garcia, G., Madrigal, L., Reiman, E. M., Arcos‐Burgos, M., Bedoya, G., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.09.005 · Cited by 60
“Almost 70% of pathological mutations in PSEN1 occur in exons 5 to 8 [4] and act through altering g-secretase activity and the production of amyloid-b peptide Ab42 [5].”
Abuelezz, N. Z., Nasr, F. E., AbdulKader, M. A., Bassiouny, A. R., & Zaky, A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.743573 · Cited by 59
Kosicek, M., Malnar, M., Goate, A., & Hecimovic, S. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.02.007 · Cited by 52
Castillo, G. M., Lukito, W., Peskind, E., Raskind, M., Kirschner, D. A., Yee, A. G., & Snow, A. D. (2000) · Journal of Neuroscience Research · doi:10.1002/1097-4547(20001101)62:3<451::aid-jnr15>3.0.co;2-f · Cited by 60
Self-citationChun, Y. S., Kwon, O.-H., & Chung, S. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.06.067 · Cited by 62
Early-Onset and Robust Amyloid Pathology in a New Homozygous Mouse Model of Alzheimer's Disease
Willuweit, A., Velden, J., Godemann, R., Manook, A., Jetzek, F., Tintrup, H., Kauselmann, G., Zevnik, B., Henriksen, G., Drzezga, A., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007931 · Cited by 61
“Accordingly, higher ratios of Ab42 over Ab40 were also observed in human patients with PS1 mutations [31].”
BackgroundInhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease
Lansbury, P. T. (1997) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(97)80018-x · Cited by 73
Wiley, J. C., Hudson, M. P., Kanning, K. C., Schecterson, L. C., & Bothwell, M. A. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03266.x · Cited by 69
“(2005) 94, 1189–1201 1189 APP, PS1 and PS2 elevate the production of Ab42, normally a minor Ab peptide species, while having variable effects on production of Ab40 (Suzuki et al. 1994; Borchelt et al. 1996; Duff et al. 1996; Scheuner et al. 1996; Citron et al. 1997; Murayama et al. 1999).”
BackgroundLocalization of presenilin–nicastrin complexes and γ‐secretase activity to the trans‐Golgi network
Siman, R., & Velji, J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01616.x · Cited by 49
“Of the 29 familial Alzheimer’s disease-linked PS-1 mutations and two PS-2 mutations examined so far, all increase the cellular secretion of the fibrillogenic 42-residue Ab variant (Scheuner et al. 1996; Citron et al. 1997; Murayama et al. 1999).”
BackgroundTesco, G., Kim, T., Diehlmann, A., Beyreuther, K. T., & Tanzi, R. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.51.33909 · Cited by 61
Self-citationContrasting Role of Presenilin-1 and Presenilin-2 in Neuronal Differentiation In Vitro
Hong, C.-S., Caromile, L., Nomata, Y., Mori, H., Bredesen, D. E., & Koo, E. H. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-02-00637.1999 · Cited by 62
“Finally, it will be important to determine whether these physiological properties of presenilins or perturbations of these properties, such as in cell death or in affecting Ab production (Scheuner et al., 1996), contribute to the pathogenesis of Alzheimer’s disease.”
BackgroundRegulation of Apoptosis by Presenilin 1
Wolozin, B. L., Alexander, P., & Palacino, J. J. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00041-4 · Cited by 63
Therapeutic Strategies to Target Calcium Dysregulation in Alzheimer’s Disease
Calvo-Rodríguez, M., Kharitonova, E. K., & Bacskai, B. J. (2020) · Cells · doi:10.3390/cells9112513 · Cited by 68
Wang, H., Megill, A., He, K., Kirkwood, A., & Lee, H.-K. (2012) · Neural Plasticity · doi:10.1155/2012/272374 · Cited by 59
“FADlinked mutations in PS1 facilitate the production of the more pathogenic Aβ42 peptide [85, 101], which is the major constituent of senile plaques found in the brains of AD patients.”
BackgroundGrimm, M. O. W., Zinser, E. G., Grösgen, S., Hundsdörfer, B., Rothhaar, T. L., Burg, V. K., Kaestner, L., Bayer, T. A., Lipp, P., Müller, U., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034095 · Cited by 59
“To rule out effects caused by the use of synthetic rather than naturally derived Ab peptides, we analyzed conditioned media of APP expressing cells, secreting Ab40 and Ab42 in a ratio of approximately 10:1 [30].”
BackgroundYamashita, S., Kiko, T., Fujiwara, H., Hashimoto, M., Nakagawa, K., Kinoshita, M., Furukawa, K., Arai, H., & Miyazawa, T. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150640 · Cited by 68
Mouse Genetic Models of Human Brain Disorders
Leung, C., & Jia, Z. (2016) · Frontiers in Genetics · doi:10.3389/fgene.2016.00040 · Cited by 69
“AD-associated PS mutations have been shown to increase the two most common isoforms of Aβ, Aβ42 and Aβ40, both of which are known to be responsible for the rate of amyloid deposition (Borchelt et al., 1996; Scheuner et al., 1996).”
BackgroundMisfolded amyloid-β-42 impairs the endosomal–lysosomal pathway
Marshall, K. E., Vadukul, D. M., Staras, K., & Serpell, L. C. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03464-4 · Cited by 61
Brooks, W. S. (2003) · Brain · doi:10.1093/brain/awg084 · Cited by 58
“The PS-1 gene product is believed to play a crucial role in amyloid precursor protein (APP) metabolism, with mutated forms resulting in increased production of the longer (42 amino acid) form of the Ab peptide (Ab42), which is more prone to aggregate to form ®brillar amyloid (Scheuner et al., 1996).”
BackgroundMohajeri, M. H., Saini, K., Schultz, J. G., Wollmer, M. A., Hock, C., & Nitsch, R. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203193200 · Cited by 59
Khan, M. F., & Falk, R. H. (2001) · Postgraduate Medical Journal · doi:10.1136/pmj.77.913.686 · Cited by 59
Tandon, A., & Fraser, P. E. (2002) · Genome biology · doi:10.1186/gb-2002-3-11-reviews3014 · Cited by 88
Leutner, S., Czech, C., Schindowski, K., Touchet, N., Eckert, A., & Müller, W. E. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01449-x · Cited by 65
Regulation of Brain G-protein Go by Alzheimer's Disease Gene Presenilin-1
Smine, A., Xu, X., Nishiyama, K., Katada, T., Gambetti, P., Yadav, S. P., Wu, X., Shi, Y.-C., Yasuhara, S., Homburger, V., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.26.16281 · Cited by 59
Binding Partners of Alzheimer's Disease Proteins: Are They Physiologically Relevant?
Van Gassen, G., Annaert, W., & Van Broeckhoven, C. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0306 · Cited by 59
Sanchez, J. S., Hanseeuw, B. J., Lopera, F., Sperling, R. A., Baena, A., Bocanegra, Y., Aguillon, D., Guzmán-Vélez, E., Pardilla-Delgado, E., Ramirez-Gomez, L., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00765-5 · Cited by 58
“Brain fibrillar Aβ accumulation associated with the PSEN1-E280A mutation is a steady process beginning decades prior to symptom onset [5, 6].”
BackgroundKarve, S. J., Ringman, J. M., Lee, A. S., Juarez, K. O., & Mendez, M. F. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6481-y · Cited by 56
“There is convergent evidence that PSEN1, PSEN2, and APP mutations cause FAD by increasing the absolute or relative amount of Ab42 derived from APP [8].”
BackgroundClinical Genetics of Alzheimer’s Disease
Zou, Z., Liu, C., Che, C., & Huang, H. (2014) · BioMed Research International · doi:10.1155/2014/291862 · Cited by 71
Altered γ‐secretase activity in mild cognitive impairment and Alzheimer's disease
Kakuda, N., Shoji, M., Arai, H., Furukawa, K., Ikeuchi, T., Akazawa, K., Takami, M., Hatsuta, H., Murayama, S., Hashimoto, Y., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201200214 · Cited by 58
“Nor has it been reported for asymptomatic FAD carriers (Ringman et al, 2008), whereas their plasma is known to contain higher levels (and percent) of A b 42 (Kosaka et al, 1997; Ringman et al, 2008; Scheuner et al, 1996).”
Functional Implications of the Presenilin Dimerization
Cervantes, S., Saura, C. A., Pomares, E., Gonzàlez-Duarte, R., & Marfany, G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404832200 · Cited by 59
Vattemi, G. N. A., Nogalska, A., Engel, W. K., D’Agostino, C., Checler, F., & Askanas, V. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0511-6 · Cited by 64
“They participate in the production of both A 1-42 and A 1-40 peptides [20, 27, 34].”
BackgroundA case for a non‐transgenic animal model of Alzheimer's disease
Stéphan, A., & Phillips, A. G. (2005) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2004.00113.x · Cited by 59
“Discoveries such as these were soon followed by demonstrations that AD-causing mutation of genes for PS proteins PS1 and PS2 also enhance the processing of APP to form amyloidogenic Ab (Scheuner et al. 1996; Sherrington et al. 1995).”
BackgroundApoptosis, Neurotrophic Factors and Neurodegeneration
Dragunow, M., MacGibbon, G. A., Lawlor, P. A., Butterworth, N. J., Connor, B. J., Henderson, C. E., Walton, M. R., Woodgate, A.-M., Hughes, P. E., & Faull, R. L. M. (1997) · Reviews in the Neurosciences · doi:10.1515/revneuro.1997.8.3-4.223 · Cited by 65
Siddappaji, K. K., & Gopal, S. (2021) · AIMS neuroscience · doi:10.3934/neuroscience.2021020 · Cited by 66
Alzheimer’s-Related Peptide Amyloid-β Plays a Conserved Role in Angiogenesis
Cameron, D. J., Galvin, C., Alkam, T., Sidhu, H., Ellison, J., Luna, S., & Ethell, D. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039598 · Cited by 58
“Ab1–42 to be produced [27,28].”
Forman, M. S., Cook, D. G., Leight, S., Doms, R. W., & Lee, V. M.-Y. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.51.32247 · Cited by 58
Intracellular Calcium Dysregulation by the Alzheimer’s Disease-Linked Protein Presenilin 2
Galla, L., Redolfi, N., Pozzan, T., Pizzo, P., & Greotti, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030770 · Cited by 64
Cerebrospinal fluid Ab40 and Ab42 natural course and clinical usefulness
Shoji, M. (2002) · Frontiers in Bioscience · doi:10.2741/a826 · Cited by 57
Watson, D. J., Selkoe, D. J., & Teplow, D. B. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3400703 · Cited by 57
Self-citationReynolds, C. A., Hong, M.-G., Eriksson, U. K., Blennow, K., Wiklund, F., Johansson, B., Malmberg, B., Berg, S., Alexeyenko, A., Grönberg, H., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq079 · Cited by 57
Mutant Presenilin 1 Increases the Expression and Activity of BACE1
Giliberto, L., Borghi, R., Piccini, A., Mangerini, R., Sorbi, S., Cirmena, G., Garuti, A., Ghetti, B., Tagliavini, F., Mughal, M. R., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m805685200 · Cited by 56
Application of immunosignatures to the assessment of Alzheimer's disease
Restrepo, L., Stafford, P., Magee, D. M., & Johnston, S. A. (2011) · Annals of Neurology · doi:10.1002/ana.22405 · Cited by 68
The neuronal sortilin-related receptor gene SORL1 and late-onset Alzheimer’s disease
Lee, J. H., Barral, S., & Reitz, C. (2008) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-008-0060-8 · Cited by 56
Humanin and the Receptors for Humanin
Matsuoka, M., & Hashimoto, Y. (2009) · Molecular Neurobiology · doi:10.1007/s12035-009-8090-z · Cited by 61
Metabolic disorder in Alzheimer’s disease
Poddar, M. K., Banerjee, S., Chakraborty, A., & Dutta, D. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00673-z · Cited by 62
Reliable Measurements of theβ-Amyloid Pool in Blood Could Help in the Early Diagnosis of AD
Pesini, P., Pérez‐Grijalba, V., Monleón, I., Boada, M., Tárraga, L., Martínez‐Lage, P., José, I. S., & Sarasa, M. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/604141 · Cited by 65
“Indeed, it is well established that Aβ blood levels are elevated before the onset of dementia in dominantinherited early AD and Downs syndrome [13, 14].”
Background
Metadata
- Authors
- Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, L., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., & Younkin, S.
- Affiliations
- Case Western Reserve University (US)
- Mayo Clinic (US)
- Karolinska Institutet (SE)
- Brigham and Women's Hospital (US)
- Takeda (Japan) (JP)
- University of Washington (US)
- University of South Florida (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1996-08
- Volume
- 2
- Issue
- 8
- Pages
- 864-870
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2101077392
- Semantic Scholar
- ce2164647cb7fb8dcec21d95359a92ec9830047a
- Cited by
- 2,599
- References
- 40
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 58 · 2023: 74 · 2022: 45 · 2021: 66 · 2020: 66 · 2019: 58 · 2018: 53 · 2017: 64 · 2016: 76 · 2015: 72 · 2014: 77 · 2013: 91 · 2012: 96
- FWCI
- 102.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, familial Alzheimer's disease, presenilin 1, presenilin 2, amyloid precursor protein, APP mutations, amyloid plaques
- MeSH terms
- Alzheimer Disease, Cells, Cultured, Female, Fibroblasts, Humans, Male, Membrane Proteins, Mutation, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Culture Media, Conditioned, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.